title: Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis.
abstract: OBJECTIVE
  To evaluate the role of corifollitropin alfa, a newly developed weekly administrated long-acting recombinant FSH (rFSH), as an alternative for daily rFSH administration in women undergoing controlled ovarian stimulation in GnRH antagonist down-regulated in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment cycles.
  
  
  METHODS
  Systematic review and meta-analysis of randomized controlled trials.
  
  
  METHODS
  University and private centers.
  
  
  METHODS
  Infertile women undergoing IVF/ICSI treatment.
  
  
  METHODS
  Comparing long-acting rFSH corifollitropin alfa versus standard daily administrated rFSH in GnRH antagonist IVF/ICSI cycles.
  
  
  METHODS
  Ongoing pregnancy rate, live birth rate, clinical pregnancy rate, miscarriage rate, duration of stimulation, amount of FSH, number of retrieved oocytes, number of mature oocytes, number of embryos obtained, fertilization rate, ovarian hyperstimulation syndrome (OHSS) incidence, and adverse events. Searches (of literature through November 2011) were conducted in Medline, Embase, Science Direct, the Cochrane Library, and databases of abstracts.
  
  
  RESULTS
  Four randomized trials involving 2,326 women were included. There was no evidence of a statistically significant difference in ongoing pregnancy rate for corifollitropin alfa versus rFSH. There was evidence of increased ovarian response and risk of OHSS in corifollitropin alfa.
  
  
  CONCLUSIONS
  In view of its equivalence and safety profile, corifollitropin alfa in combination with daily GnRH antagonist seems to be an alternative for daily rFSH injections in normal responder patients undergoing ovarian stimulation in IVF/ICSI treatment cycles.
authors.affiliation: Department of Obstetrics and Gynaecology, Center for Reproductive Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt. m.a.youssef@amc.uva.nl
authors.forename: Mohamed Abdelfattah
authors.initials: MA
authors.lastname: Mahmoud Youssef
authors.forename: Madelon
authors.initials: M
authors.lastname: van Wely
authors.forename: Ismail
authors.initials: I
authors.lastname: Aboulfoutouh
authors.forename: Walid
authors.initials: W
authors.lastname: El-Khyat
authors.forename: Fulco
authors.initials: F
authors.lastname: van der Veen
authors.forename: Hesham
authors.initials: H
authors.lastname: Al-Inany
mesh_terms: D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D005307:Fertilization in Vitro; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007246:Infertility / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D020554:Sperm Injections, Intracytoplasmic; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; C437186:follicle stimulating hormone, human, with HCG C-terminal peptide